S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
Log in

Allena Pharmaceuticals Stock Forecast, Price & News

-0.05 (-2.87 %)
(As of 03/2/2021 12:00 AM ET)
Today's Range
Now: $1.69
50-Day Range
MA: $1.79
52-Week Range
Now: $1.69
Volume538,875 shs
Average Volume3.06 million shs
Market Capitalization$64.71 million
P/E RatioN/A
Dividend YieldN/A
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and moderate to severe chronic kidney diseases. Allena Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Newton, Massachusetts.
Allena Pharmaceuticals logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:ALNA
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$0.73 per share


Net Income$-47,340,000.00


Market Cap$64.71 million
Next Earnings Date3/15/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.33 out of 5 stars

Medical Sector

683rd out of 1,969 stocks

Biological Products, Except Diagnostic Industry

91st out of 177 stocks

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
-0.05 (-2.87 %)
(As of 03/2/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALNA News and Ratings via Email

Sign-up to receive the latest news and ratings for ALNA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Allena Pharmaceuticals (NASDAQ:ALNA) Frequently Asked Questions

Is Allena Pharmaceuticals a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allena Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Allena Pharmaceuticals stock.
View analyst ratings for Allena Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Allena Pharmaceuticals?

Wall Street analysts have given Allena Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Allena Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Allena Pharmaceuticals?

Allena Pharmaceuticals saw a decline in short interest in the month of February. As of February 12th, there was short interest totaling 902,100 shares, a decline of 33.7% from the January 28th total of 1,360,000 shares. Based on an average daily volume of 2,370,000 shares, the days-to-cover ratio is currently 0.4 days.
View Allena Pharmaceuticals' Short Interest

When is Allena Pharmaceuticals' next earnings date?

Allena Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for Allena Pharmaceuticals

How were Allena Pharmaceuticals' earnings last quarter?

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) announced its quarterly earnings results on Saturday, November, 14th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.01.
View Allena Pharmaceuticals' earnings history

How has Allena Pharmaceuticals' stock price been impacted by COVID-19?

Allena Pharmaceuticals' stock was trading at $1.26 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ALNA stock has increased by 34.1% and is now trading at $1.69.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ALNA?

5 brokerages have issued 1 year price targets for Allena Pharmaceuticals' shares. Their forecasts range from $5.00 to $18.00. On average, they anticipate Allena Pharmaceuticals' stock price to reach $10.40 in the next year. This suggests a possible upside of 515.4% from the stock's current price.
View analysts' price targets for Allena Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Allena Pharmaceuticals' key executives?

Allena Pharmaceuticals' management team includes the following people:
  • Dr. Alexey L. Margolin, Co-Founder & Chairman (Age 68, Pay $734.38k)
  • Dr. Louis Brenner, Pres, CEO & Director (Age 51, Pay $507.28k)
  • Mr. Robert Gallotto, Co-Founder & Strategic Adviser (Age 56)
  • Dr. Richard D. Katz, CFO, Principal Financial Officer & Principal Accounting Officer (Age 57)
  • Mr. Geoffrey A. Swire, Sr. VP of Corp. Devel., Acting COO & Interim Principal Operating Officer (Age 49)
  • Mr. Hugh Wight, Sr. VP of Technical Operations
  • Ms. Alicja Januszewicz Ph.D., VP of People & Culture
  • Dr. David J. Clark, Chief Medical Officer (Age 56)

What is Louis Brenner, M.D.'s approval rating as Allena Pharmaceuticals' CEO?

1 employees have rated Allena Pharmaceuticals CEO Louis Brenner, M.D. on Glassdoor.com. Louis Brenner, M.D. has an approval rating of 100% among Allena Pharmaceuticals' employees. This puts Louis Brenner, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Allena Pharmaceuticals' key competitors?

What other stocks do shareholders of Allena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), VYNE Therapeutics (VYNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Acasti Pharma (ACST) and Miragen Therapeutics (MGEN).

When did Allena Pharmaceuticals IPO?

(ALNA) raised $80 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,300,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Allena Pharmaceuticals' stock symbol?

Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA."

Who are Allena Pharmaceuticals' major shareholders?

Allena Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Worth Venture Partners LLC (1.33%), Renaissance Technologies LLC (0.65%), BlackRock Inc. (0.43%) and Golden Green Inc. (0.10%). Company insiders that own Allena Pharmaceuticals stock include Edward Wholihan and Louis Md Brenner.
View institutional ownership trends for Allena Pharmaceuticals

Which major investors are buying Allena Pharmaceuticals stock?

ALNA stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Worth Venture Partners LLC, Golden Green Inc., and BlackRock Inc..
View insider buying and selling activity for Allena Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Allena Pharmaceuticals?

Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allena Pharmaceuticals' stock price today?

One share of ALNA stock can currently be purchased for approximately $1.69.

How much money does Allena Pharmaceuticals make?

Allena Pharmaceuticals has a market capitalization of $64.71 million. The company earns $-47,340,000.00 in net income (profit) each year or ($2.10) on an earnings per share basis.

How many employees does Allena Pharmaceuticals have?

Allena Pharmaceuticals employs 32 workers across the globe.

What is Allena Pharmaceuticals' official website?

The official website for Allena Pharmaceuticals is www.allenapharma.com.

Where are Allena Pharmaceuticals' headquarters?

Allena Pharmaceuticals is headquartered at ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462.

How can I contact Allena Pharmaceuticals?

Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company can be reached via phone at 617-467-4577.

This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.